
    
      The study will provide data on the tolerance, safety and acceptance of Depo-Eligard®
      (leuproreline acetate) when used in routine clinical practice. Data on efficacy parameters
      such as testosterone, PSA levels, symptoms and treatment failure, if available will be
      collected.It will reflect the way Depo-Eligard® is used in routine clinical practice and how
      PSA, testosterone levels, symptoms and treatment failure, are used as parameters in the
      treatment for Prostate Cancer.

      Patient data will be collected after a treatment period of six months.
    
  